Skip to main content

Manufacturing and scale up challenges in Allogeneic Cell Therapy Development

25 Jun 2024
Salon B
  • High degree of batch-to-batch variability may lead to inconsistent cell performance in vivo.
  • Given the plethora of variables in cell therapy upstream and downstream processing, there is a need for a systematic development of DS and DP processes for cell therapy especially allogeneic cell therapy.
  • The discussion will highlight challenges at various stages of development and provide some thoughts around potential solution
Industry Expert
Shankar Swaminathan, Associate Director Drug Product Development - Astellas Institute for Regenerative Medicine